WAUI
BBIO icon

WELLINGTON-ALTUS USA INC.’s BridgeBio Pharma BBIO Stock Holding History

WELLINGTON-ALTUS USA INC.’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9K Hold
201
– – 0.01% 546
2026
Q1 		$15K Buy
+201
New +$14.6K 0.01% 571

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

WELLINGTON-ALTUS USA INC.'s BBIO Position: Q2 2026 in Review

WELLINGTON-ALTUS USA INC. held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 201 shares worth $14.9K. The position accounts for 0.01% of the portfolio, ranked #546.

WELLINGTON-ALTUS USA INC. first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $15K in Q1 2026. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • WELLINGTON-ALTUS USA INC. held 201 shares of BridgeBio Pharma worth $14.9K as of Q2 2026.
  • WELLINGTON-ALTUS USA INC. left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up 0.01% of WELLINGTON-ALTUS USA INC.'s portfolio in Q2 2026, its #546 holding.
  • WELLINGTON-ALTUS USA INC. first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • WELLINGTON-ALTUS USA INC.'s BridgeBio Pharma position peaked at $15K in Q1 2026.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on WELLINGTON-ALTUS USA INC.'s 13F filing for Q2 2026, filed 17 Sep 2026.